M&A / Deals GSK bolts on siRNA drug from China’s SiranBio in $1bn deal PharmaphorumGSK has extended its pipeline of siRNA drugs once again by licensing an ALK7-targeted therapy for cardiometabolic diseases from SiranBio.Read full story pharminent May 6, 2026 (Last updated: May 6, 2026) Pharmaphorum GSK has extended its pipeline of siRNA drugs once again by licensing an ALK7-targeted therapy for cardiometabolic diseases from SiranBio. Read full story Post navigation Previous: CellCentric raises $220M for a ‘transformative’ multiple myeloma medicineNext: CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026 Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
